Therefore, in vitro and in vivo studies suggest a potentially important role for the NLRP3 inflammasome in the pathogenesis of AD and identify the NLRP3–caspase-1 axis as a potential target for AD therapy. This evidence concerns the gene NLRP3 and Alzheimer disease.